Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glucopyranosyl Lipid A · 1 trial · 1 indication
Number of participants with AEs
| Arm | Type | Description |
|---|---|---|
| SAR439794 [PE SLIT + GLA)] | EXPERIMENTAL | GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks |
| Placebo for GLA + SLIT PE | EXPERIMENTAL | Placebo for GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks |
| Placebo for GLA + Placebo for SLIT PE | PLACEBO_COMPARATOR | Placebo for GLA repeated doses then Placebo for SLIT PE escalating doses once daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| Glucopyranosyl Lipid A (GLA) | DRUG | Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual |
| Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) | DRUG | Pharmaceutical form:Solution Route of administration: Sublingual |
| Placebo for GLA | DRUG | Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual |
| Placebo for SLIT PE | DRUG | Pharmaceutical form:Solution Route of administration: Sublingual |
Inclusion criteria : * Male or female patients, between 18 and 55 years of age, inclusive and adolescents between 12 and 17 years of age (after enrollment of 20 adult patients completed the 6 weeks dose escalation period and the safety and tolerability is deemed acceptable). * Physician-diagnosed p...
Glucopyranosyl Lipid A is an investigational small molecule being developed for food allergy, specifically studied in peanut allergic adult and adolescent patients. It is administered sublingually on a daily basis. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
The specific molecular target of Glucopyranosyl Lipid A is not disclosed in available information. It is being studied as a sublingual daily treatment for peanut allergy, a form of food allergy, in adult and adolescent patients. The drug's mechanism of action has not been publicly detailed.
Glucopyranosyl Lipid A is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 1 clinical development for the treatment of food allergy, specifically peanut allergy.
Glucopyranosyl Lipid A is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. A Phase 1 clinical trial has been completed, and the drug is not yet available for commercial use.
Glucopyranosyl Lipid A has been studied in one completed Phase 1 clinical trial, identified as NCT03463135. This trial assessed the tolerability and safety of SAR439794 after repeated sublingual daily administration in peanut allergic adult and adolescent patients. The trial enrolled 27 participants in the United States.
Yes, Glucopyranosyl Lipid A is also known as SAR439794. The Phase 1 clinical trial NCT03463135 evaluated SAR439794, which is the same drug as Glucopyranosyl Lipid A, in peanut allergic patients. This alternative name may be used in clinical trial registries and scientific literature.